Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

33 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-11-16

Study Completion Date

2013-08-21

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine the potential of denosumab to treat Hypercalcemia of Malignancy in patients with elevated serum calcium who do not respond to recent treatment with intravenous bisphosphonates by lowering corrected serum calcium \</= 11.5 mg/dL (2.9 millimoles /L) by day 10.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks

NCT02051218

Metastatic Breast Cancer Metastatic Prostate Cancer Bone Metastases

ACTIVE_NOT_RECRUITING PHASE3

Denosumab for Prolonging Bone Metastasis-Free Survival in Men With Hormone-Refractory Prostate Cancer

NCT01824342

Castrate-resistant Prostate Cancer

COMPLETED PHASE3

Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)

NCT01077154

Breast Cancer

TERMINATED PHASE3

Study of Denosumab in Subjects With Giant Cell Tumor of Bone

NCT00680992

Cancer Giant Cell Tumors Giant Cell Tumor of Bone +1 more

COMPLETED PHASE2

Denosumab for Breast Cancer With Bone Mets

NCT01952054

Breast Cancer

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer Hypercalcemia of Malignancy Colon Cancer Endocrine Cancer Head and Neck Cancer Kidney Cancer Lung Cancer Lymphoma Metastatic Cancer Multiple Myeloma Parathyroid Neoplasms Renal Cancer Thyroid Cancer Hodgkin's Lymphoma Non-Hodgkin's Lymphoma Non-Small Cell Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

denosumab

Eligible subjects will receive denosumab at a dose of 120 mg subcutaneously (SC) every 4 weeks (Q4W) with a loading dose of 120 mg SC on study days 8 and 15.

Group Type EXPERIMENTAL

denosumab

Intervention Type DRUG

120 mg subcutaneously (SC) every 4 weeks with a loading dose of 120 mg SC on study days 8 and 15.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

denosumab

120 mg subcutaneously (SC) every 4 weeks with a loading dose of 120 mg SC on study days 8 and 15.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Hypercalcemia of Malignancy (HCM) as defined as documented histologically or cytologically confirmed cancer and a corrected serum calcium (CSC) \> 12.5 mg/dL (3.1 millimoles /L) at screening by local laboratory
* Last IV bisphosphonate treatment must be \>/= to 7 days and \</= to 30 days before the screening corrected serum calcium
* Adults (\>/=18 years)
* Adequate organ function as defined by the following criteria:
* serum aspartate aminotransferase (AST) \</= 5 x upper limit of normal (ULN)
* serum alanine aminotransferase (ALT) \</= 5 x upper limit of normal
* serum total bilirubin \</= 2 x upper limit of normal

Exclusion Criteria

* Evidence of benign hyperparathyroidism, hyperthyroidism, adrenal insufficiency, vitamin D intoxication, milk alkali syndrome, sarcoidosis, or other granulomatous disease
* Receiving dialysis for renal failure
* Treatment with thiazides, calcitonin, mithramycin, or gallium nitrate within their window of expected therapeutic effect (as determined by the physician) prior to the date of the screening CSC
* Treatment with cinacalcet within 4 weeks prior to the date of the screening CSC
* Thirty days or less since receiving an investigational product (other than denosumab) or device (ie, does not have marketing authorization; thalidomide use is allowed) in another clinical study
* Known sensitivity to any of the products to be administered during the study (eg, mammalian derived products)
* Female subject is pregnant or breast feeding, or planning to become pregnant within 7 months after the end of treatment
* Female subject of childbearing potential is not willing to use 2 highly effective methods of contraception during treatment and for 7 months after the end of treatment
* Subject will not be available for follow-up assessment.
* Any organic or psychiatric disorder that, in the opinion of the investigator, might prevent the subject from completing the study or interfere with the interpretation of the study results

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No